WHO head wants Covid-19 vaccine patents waived to increase supply

The head of the World Health Organization called for patent rights to be waived until the end of the pandemic so that vaccine supplies can be dramatically increased

Topics
Coronavirus Vaccine | Coronavirus | WHO

AP  |  Geneva 

Photo: Bloomberg
Photo: Bloomberg

The head of the World Health Organization called Friday for patent rights to be waived until the end of the pandemic so that vaccine supplies can be dramatically increased, saying these unprecedented times warrant the move.

At a press briefing, chief Tedros Adhanom Ghebreyesus said countries with their own vaccine capacity should start waiving intellectual property rights as provided in special emergency provisions from the World Trade Organization.

These provisions are there for use in emergencies, Tedros said.

If now is not a time to use them, then when? He said the would be meeting soon with representatives of the industry to identify bottlenecks in production and discuss how to solve them.

The Associated Press found factories on three continents whose owners say they could start producing hundreds of millions of COVID-19 vaccines at short notice if only they had the blueprints and technical know-how.

But that knowledge belongs to the large pharmaceutical companies that have produced the first three vaccines authorized by countries including Britain, the European Union and the US -- Pfizer, Moderna and AstraZeneca. The factories are all still awaiting responses.

Tedros commended AstraZeneca for sharing its COVID-19 vaccine technology with companies including the Serum Institute of India, but said the main disadvantage of this approach is the lack of transparency.

Pharmaceutical companies that took taxpayer money from the US or Europe to develop inoculations at unprecedented speed say they are negotiating contracts and exclusive licensing deals with producers on a case-by-case basis because they need to protect their intellectual property and ensure safety.

Tedros noted that although the UN-backed effort known as COVAX has delivered vaccines to more than 20 countries this week, the amounts are only enough to protect about 2 to 3 percent of each country's population.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Sat, March 06 2021. 08:49 IST
RECOMMENDED FOR YOU